GFAP and obesity due to melanocortin 4 receptor deficiency: GFAP: Model 6 was again best fitting and showed faster average increases in those with Stage 3 kidney disease, higher average values in those with Stage 3 kidney disease, or higher APOE‐npscore and lower average values in men and people with obesity (Table S5; Figure S5H–K).